In the past few years, small peptides having anticancer properties have emerged as a potential avenue for cancer therapy. Compared to current anti-cancer chemotherapeutic drugs (or small molecules), anticancer peptides (ACPs) have numerous advantageous properties, such as high specificity, low production cost, high tumor penetration, ease of synthesis and modification. However, in wet lab setups, identification and characterization of novel ACPs is a time-consuming and labor-intensive process. Therefore, in silico designing of anticancer peptides is beneficial, prior to their synthesis and characterization. This approach is less time consuming and more cost-effective. In this chapter, we discuss a web-based tool, AntiCP (http://crdd.osdd.net/raghava/anticp/), for designing ACPs.
Anti-cancer peptides Machine learning Support vector machine
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Risso A, Braidot E, Sordano MC et al (2002) BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 22:1926–1935CrossRefPubMedPubMedCentralGoogle Scholar
Hui L, Leung K (2002) Chen HM The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 22:2811–2816PubMedGoogle Scholar
Kim S, Kim SS, Bang YJ et al (2003) In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 24:945–953CrossRefPubMedGoogle Scholar
Fang X-Y, Chen W, Fan J-T et al (2013) Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction. Toxicol Appl Pharmacol 267:95–103. doi:10.1016/j.taap.2012.12.010CrossRefPubMedGoogle Scholar
Kim SE, Kim HH, Kim JY et al (2000) Anticancer activity of hydrophobic peptides from soy proteins. Biofactors 12:151–155CrossRefPubMedGoogle Scholar
Kozłowska K, Nowak J, Kwiatkowski B, Cichorek M (1999) ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp Toxicol Pathol Off J 51:89–92. doi:10.1016/S0940-2993(99)80074-8CrossRefGoogle Scholar
Sok M, Sentjurc M, Schara M (1999) Membrane fluidity characteristics of human lung cancer. Cancer Lett 139:215–220CrossRefPubMedGoogle Scholar
Hariharan S, Gustafson D, Holden S et al (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18:1400–1407. doi:10.1093/annonc/mdm140CrossRefPubMedGoogle Scholar